| | NM | NM + AEHE | DM | DM + LAEHE | DM + HAEHE | DM + Gli |
|---|
Day 0 | 20.4 ± 1.0 | 21.1 ± 1.3 | 9.6 ± 0.9a
| 9.8 ± 0.9a
| 10.1 ± 1.1a
| 9.9 ± 0.9a
|
Day 14 | 21.2 ± 1.2 | 21.6 ± 1.2 | 9.4 ± 1.1a
| 12.4 ± 1.2a,b,c
| 16.3 ± 1.3a,b,c
| 15.8 ± 1.2a,b,c
|
Day 28 | 20.9 ± 1.2 | 22.4 ± 1.1 | 9.7 ± 1.2a
| 16.4 ± 1.1a,b,c
| 18.9 ± 1.4a,b,c
| 18.6 ± 1.6a,b,c
|
- Values are expressed as mean ± SD in each group. NM group: normal control rats treated with vehicle alone; NM + AEHE group: normal control rats treated with AEHE (100 mg/kg b.w.); DM group: diabetic control rats treated with vehicle alone; DM + LAEHE group: diabetic rats were given AEHE (100 mg/kg b.w.); DM + HAEHE group: diabetic rats were given AEHE (200 mg/kg b.w.); DM + Gli group: diabetic rats were given glibenclamide (30 mg/kg b.w.). aindicates statistical significance of P < 0.05 compared to the NM group; bindicates statistical significance of P < 0.05 compared to the DM group, cindicates statistical significance of P < 0.05 compared to the same group at day 0.
